Hainan Poly Pharm Past Earnings Performance
Past criteria checks 1/6
Hainan Poly Pharm has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 22.3% per year. Hainan Poly Pharm's return on equity is 11.8%, and it has net margins of 20.7%.
Key information
14.5%
Earnings growth rate
13.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 22.3% |
| Return on equity | 11.8% |
| Net Margin | 20.7% |
| Last Earnings Update | 30 Sep 2023 |
Revenue & Expenses BreakdownBeta
How Hainan Poly Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,788 | 369 | 483 | 235 |
| 30 Jun 23 | 1,845 | 403 | 499 | 262 |
| 31 Mar 23 | 1,812 | 397 | 464 | 268 |
| 31 Dec 22 | 1,806 | 421 | 457 | 263 |
| 30 Sep 22 | 1,743 | 482 | 338 | 283 |
| 30 Jun 22 | 1,681 | 479 | 331 | 252 |
| 31 Mar 22 | 1,603 | 457 | 327 | 236 |
| 01 Jan 22 | 1,509 | 417 | 315 | 229 |
| 30 Sep 21 | 1,543 | 513 | 317 | 230 |
| 30 Jun 21 | 1,410 | 474 | 299 | 224 |
| 31 Mar 21 | 1,291 | 449 | 264 | 217 |
| 31 Dec 20 | 1,189 | 407 | 250 | 191 |
| 30 Sep 20 | 1,124 | 380 | 280 | 237 |
| 30 Jun 20 | 1,000 | 340 | 258 | 188 |
| 31 Mar 20 | 964 | 311 | 265 | 186 |
| 31 Dec 19 | 950 | 301 | 266 | 184 |
| 30 Sep 19 | 830 | 266 | 240 | 168 |
| 30 Jun 19 | 725 | 231 | 196 | 158 |
| 31 Mar 19 | 687 | 220 | 197 | 145 |
| 31 Dec 18 | 624 | 181 | 187 | 138 |
| 30 Sep 18 | 528 | 159 | 151 | 119 |
| 30 Jun 18 | 445 | 137 | 117 | 116 |
| 31 Mar 18 | 371 | 119 | 102 | 79 |
| 31 Dec 17 | 325 | 98 | 100 | 63 |
| 30 Sep 17 | 298 | 89 | 115 | 27 |
| 30 Jun 17 | 275 | 78 | 129 | 0 |
| 31 Mar 17 | 260 | 72 | 124 | 0 |
| 31 Dec 16 | 248 | 70 | 115 | 0 |
| 30 Jun 16 | 214 | 56 | 102 | 0 |
| 31 Mar 16 | 193 | 50 | 90 | 0 |
| 31 Dec 15 | 203 | 51 | 97 | 0 |
| 31 Dec 14 | 165 | 37 | 81 | 0 |
| 31 Dec 13 | 132 | 25 | 65 | 0 |
Quality Earnings: 300630 has a large one-off gain of CN¥81.1M impacting its last 12 months of financial results to 30th September, 2023.
Growing Profit Margin: 300630's current net profit margins (20.7%) are lower than last year (27.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300630's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: 300630's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300630 had negative earnings growth (-23.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.6%).
Return on Equity
High ROE: 300630's Return on Equity (11.8%) is considered low.